Fenbendazole as a potential anticancer drug

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 355-362

  Duan, Qiwen ^a,b   Liu, Yanfeng ^a   Rockwell, Sara ^a,c  

^a YALE CANCER CENTER   (United States)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Benzamidazoles; EMT6 cells; Fenbendazole; Hypoxia; Radiation therapy; Tumor microenvironments

Indexed keywords

DOCETAXEL; FENBENDAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CELL CULTURE; CELL HYPOXIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; FEMALE; IN VITRO SELECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; FENBENDAZOLE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE;

EID: 84875878997     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Keller WC: Fenbendazole. (WHO Food Additive Series 29) available at http://www.inchem.org/documents/jecfa/jecmono/v29je04.htm. Last accessed January 2, 2013.
2. Pritchett KR and Johnson NA: A review of treatments for the eradication of pinworm infections from laboratory rodent colonies, Contemp Top Lab Anim Sci 41: 36-46, 2002.
3. Villar D, Cray C, Zaias J and Altman NH: Biological effects of fenbendazole in rats and mice: A review. J Am Assoc Lab Anim Sci 46: 8-15, 2007.
4. Rockwell S: In vivo-in vitro tumor systems: New models for studying the response of tumors to therapy. Lab Anim Sci 27: 831-851, 1972.
5. Rockwell S: Use of hypoxia-directed drugs in the therapy of solid tumors. Semin Oncol 19: 29-40, 1992.
6. Rockwell S, Dobrucki IT, Kim EY, Marrison ST and Vu VT: Hypoxia and radiation therapy: Past history, ongoing research, and future promise. Cur Mol Med 9: 441-459, 2009.
7. Rockwell S, Liu Y and Higgins SA: Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. Breast Cancer Res Treat 90: 233-239, 2005.
8. Rockwell S, Liu Y, Seow HA, Ishiguro K, Baumann RP, Penketh PG, Shyam K, Glazer PM and Sartorelli AC: Preclinical evaluation of laromustine for use in combination with radiation therapy in the treatment of solid tumors. Int J Radiat Biol 88: 277-285, 2012.
9. Kim EY, Liu Y, Akintujoye OM, Shyam K, Grove TA, Sartorelli AC and Rockwell S: Preliminary studies with a new hypoxiaselective cytotoxin, KS119W, in vitro and in vivo. Radiat Res 178: 126-137, 2012.
10. Duan Q, Liu Y, Booth C and Rockwell S: Use of fenbendazole-containing therapeutic diets for mice in experimental cancer therapy studies. J Am Assoc Lab Anim Sci 51: 224-230, 2012.
11. Dawson PJ, Gutteridge WE and Gull K: A comparison of the interaction of antihelminth benzimidazoles with tubulin isolated from mammalian tissue and the parasitic nematode Ascaridia galli. Biochem Pharm 33: 1069-1074, 1984.
12. Lacey E: The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int J Paracytol 7: 885-936, 1988.
13. Spagnuolo PA, Hu J, Hurren R, Wang X, Gronda M, Sukhai MA, Di Meo A, Boss J, Ashall I, Zavareh RB, Fine N, Simpson CD, Sharmeen S, Rottapel R and Schimmer AD: The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 115: 4824-4833, 2009.
14. Düwel D: Fenbendazole II. Biological properties and activity. Pestic Sci 8: 550-555, 1977.
15. Pritchard RK, Kelly JD, Bolin TD, Duncombe VM and Fagan MR: The effect of iron and protein deficiency on plasma levels and parasite uptake of [14C]fenbendazole in rats infected with Nippostrongylus brasiliensis. Aust J Exper Biol Med Sci 59: 567-573, 1981.
16. Tannock I, Hill R, Bristow R and Harrington L: The Basic Science of Oncology. 4th edition, McGraw-Hill, New York, NY, 2004.
17. Bai R-Y, Staedtke V, Aprhys CM and Gallia GL, Riggins GJ: Antiparasitic mebendazole shows survival benefit in two preclinical models of glioblastoma multiforme. Neuro Oncol 13: 974-892, 2011
18. Gao P, Dang CV and Watson J: Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins. J Am Assoc Lab Anim Sci 47: 37-40, 2008.
19. Chung I, Barrows C, Wilson A, Rummel N, Badaruddin S, Mizokami A, Banyard J and Zetter B: Benzimidazole as novel therapeutic agent for metastatic prostate cancer. Poster session presented at the Annual Meeting of the American Association for Cancer Research, Washington DC, April 17-21, 2010.
20. Overgaard J: Hypoxic radiosensitization: Adored and ignored. J Clin Oncol 25: 4066-4074, 2007.
21. Gupta RP, Larroquette CA and Agrawal KC: Potential radiosensitizing agents. 5. 2-Substituted benzimidazole derivatives. J Med Chem 25: 1342-1346, 1982.
22. Seaton A, Higgins C, Mann J, Baron A, Bailly C, Neidle S and van den Berg H: Mechanistic and antiproliferative studies of two novel, biologically-active bis-benzimidazoles. Eur J Cancer 39: 2548-2555, 2003.
23. Soderlind K-J. Gorodetsky B, Singh AK, Bacher NR, Miller GG and Lown JW: Bis-benzimidazole anticancer agents: targeting human tumor helicases. Anticancer Drug Des 14: 19-36, 1999.
24. Singh AK and Lown JW: Design, synthesis and antitumor cytotoxicity of novel bis-benzimidazoles. Anticancer Drug Des 15: 265-275, 2000.
25. Institute of Laboratory Animal Sciences, National Research Council: Guide for the care and use of laboratory animals. National Academy Press. Washington DC, 1996.
26. Kallman RF: Rodent Tumors Models in Experimental Cancer Therapy. Plenum Press, New York, NY, 1987.
27. Steel GG: Terminology in the description of drug radiation interactions. Int J Radiat Oncol Biol Phys 5: 1145-1150, 1979.